Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.

Alexandre SeprianoAndrea RegelDésirée van der HeijdeJürgen BraunXenofon BaraliakosRobert LandewéFilip Van den BoschLouise FalzonSofia Ramiro

Published in: RMD open (2017)

New evidence supports the efficacy and safety of TNFi both in r-axSpA and nr-axSpA. Secukinumab is the first drug targeting the IL-17 pathway in r-axSpA that has shown efficacy.

Keyphrases

ankylosing spondylitis
cancer therapy
disease activity
clinical practice
rheumatoid arthritis
drug delivery
emergency department
adverse drug
electronic health record